A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days.

An aqueous dispersion of particles comprising a resin having at least one repeating unit of formula I, II and/or III and which is obtainable by contacting in a liquid comprising water, a compound A comprising at least 2 functional groups selected from the group of functional groups —X—C(═O)—CHR1-C(═O)—R2, —X—C(═O)—C≡C—R2; or —X—C(═O)—CR1=CR2-NR11R12, the functional groups are linked by a linking group comprising a polyester, polyether, polyolefin, polydimethylsiloxane or polycarbonate chain with a compound B comprising at least two —NH.sub.2, —NH.sub.3.sup.+ or —N═C═O, wherein X, R1, R2, R3, R11 and R12 have the same meaning as that defined in the claims and w. The invention also includes a method of producing the aqueous dispersion.

##STR00001##

The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.

A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.

Provided herein are methods and pharmaceutical compositions related to the bacteria and microbial extracellular vesicles (mEVs) of Prevotella histicola Strain C that are useful as therapeutic agents, e.g., for treating inflammatory diseases (e.g., a neuroinflammatory disease).

A particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%, and a process for preparation of the hollow particle, which includes granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.

A drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a pharmacologically active agent over an extended time period. As such, the drug delivery system finds significant utility in chronic drug administration. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods for manufacturing and using the drug delivery system are also provided.

Methods for treating or prophylaxis of a cryptosporidium infection using compositions comprising a structure disclosed herein. Also provided are pharmaceutical compositions and kits for alleviating the symptoms of, for treating, or for preventing the occurrence of cryptosporidium infection. The kits comprise one or more compounds having a structure disclosed herein, such as in an oral composition, and instructions for use, storage, and the like.

The invention relates to a coating material for use in a hot-melt coating method, said material containing as the main constituent one or more polyglycerol fatty acid, each obtained by way of a complete or partial esterification of a linear or branched polyglycerol containing two to eight glyceryl units with one or more fatty acids, each containing 6 to 22 carbon atoms.

Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.